医药大佬“变向借壳”上港股,高瓴、淡马锡、红杉谁是大赢家?

市场资讯
13 Oct 2024

来源:野马财经亿腾医药的一条腿已迈进港股市场。四年前市值超百亿港元、如今不到10个亿港元的嘉和生物-B(简称“嘉和生物”,6998.HK)近期又受到市场持续关注,因为不久前刚宣布要与亿腾医药合并,这被称为“港股18A市场首个反向收购案例”。(港股“18A”,即香港交易所《上市规则》中“主板上市规则”的第十八条A章中,允许未盈利和没有收入的生物科技公司上市的条款。 )前几日,嘉和生物宣布以换股形式与...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10